Indoco Remedies · NSE: INDOCO · BSE: 532612
Q1 FY22 results · Apr–Jun 2021
Indoco Remedies reported revenue from operations of ₹386.75 crore (up 40.2% from Q1 FY21) and net profit of ₹39.66 crore (up 132.7% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 386.75 | 275.86 | +40.2% | 305.14 | +26.7% |
| Other income | 0.86 | 0.26 | +230.8% | 1.98 | −56.6% |
| Total income | 387.61 | 276.12 | +40.4% | 307.12 | +26.2% |
| Profit before tax | 61.29 | 24.03 | +155.1% | 33.56 | +82.6% |
| Net profit for the period | 39.66 | 17.04 | +132.7% | 25.00 | +58.6% |
| EPS, basic (₹) | 4.30 | 1.85 | +132.4% | 2.71 | +58.7% |
| Net margin (%) | 10.3 | 6.2 | 8.2 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 386.49 | 275.86 | +40.1% | 304.85 | +26.8% |
| Other income | 0.86 | 0.26 | +230.8% | 1.97 | −56.3% |
| Total income | 387.35 | 276.12 | +40.3% | 306.82 | +26.2% |
| Profit before tax | 61.21 | 24.24 | +152.5% | 33.45 | +83.0% |
| Net profit for the period | 39.61 | 17.23 | +129.9% | 24.91 | +59.0% |
| EPS, basic (₹) | 4.30 | 1.87 | +129.9% | 2.70 | +59.3% |
| Net margin (%) | 10.2 | 6.2 | 8.2 |
Consolidated
- Filed with BSE
- 11 Aug 2021, 16:26 IST
- Board meeting
- 11 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Aug 2021, 16:26 IST
- Board meeting
- 11 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE